Bayer announces FDA-approved breakthrough treatment for anti-cancer drug Aliqopa

Today, bayer(http://announced that its anti-cancerdrug(http://Aliqolisib has been identified by theFDA(http://as a breakthrough therapy for patients with recurrent marginal icilloma (zone marginal lyoma, MZL) who have received both treatmentsAbout AliqopaAliqopa, developed by Bayer, is an intravenous phospholipidinol-3-kinase (phosphatesitol-3-kinase, PI3K) inhibitorPreclinical studies have shown that Aliqopa is able to inhibit pi3K-alpha and PI3K-xenon, two kinase subtypes, which are mainly expressed in malignant B cells at the sub-nanomolar levelThe PI3K signaling pathway is important in cell growth, survival, and metabolism, and the loss of control of this signaling pathway can easily trigger NHLAliqopa induces tumor cell death and inhibits the proliferation of primary malignant B cellsAliqopa inhibits several key cellular signaling pathways, including B-cell receptor (BCR) signal transduction, CXCR12-mediated malignant B-cell kineticization, and NF-B signal transduction in lymphoma cell linesAliqopa was awarded an FDA-issued orphan drug in 2015 and 2017 for the treatment of FL and MZL, respectivelyIt was approved in September 2017 for accelerated approval to treat adult patients with recurrent FL and have undergone systemic therapy at least twiceThis breakthrough therapy was awarded based on the positive results of phase 2trial(http://CHRONOS-1Preliminary resultsanalysis of(http://showed that the total remission rate (ORR) for the MZL subgroup, which had previously received at least two treatments, was 69.6%, compared with 59.2% for the entire iNHL group